For the eight primary breast cancer patients with HER2 amplification in cfDNA, the follow-up time is insufficient to inform us as to whether the presence of circulating amplified HER2 DNA is predictive of recurrent disease. This evidence concerns the gene ERBB2 and breast cancer.